Corvus Pharmaceuticals, Inc.

NASDAQ: CRVS · Healthcare · Biotechnology

PublicHQ South San Francisco, CA · San MateoCIK 0001626971Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 67DQ —GM —SS 59

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, balance-sheet leverage · ↓ Piotroski F, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$15.3M

Employees

as of 2026-09-10

Market cap

$1.1B

as of 2026-09-10

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$15.3M-$15.3M2025

Operating income-$43.0M-$43.0M2025

Total assets$71.1M$71.1M2025

Liabilities$9.9M$9.9M2025

Equity$61.2M$61.2M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Corvus Pharmaceuticals, Inc.’s financial profile?

Corvus Pharmaceuticals, Inc. earned -$15.3M in FY2025 net income.

Peers · Healthcare

Odyssey Therapeutics, Inc.——Jade Biosciences, Inc.——Lumexa Imaging Holdings, Inc. Common Stock——Replimune Group, Inc.——Alto Neuroscience, Inc.——Apnimed, Inc.——

Neighbors

San Mateo →

Meta Platforms, Inc.$201.0B86A Gilead Sciences, Inc.$29.4B87A Robinhood Markets, Inc.$4.5B67B Equinix, Inc.$9.2B74B Electronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$052D

Key facts

CEORichard A. Miller

SectorHealthcare

IndustryBiotechnology

HeadquartersSouth San Francisco, CA

ExchangeNASDAQ: CRVS

Employees37

IPO date2016-03-23

Latest filings

10-Q2026-08-06 8-K2026-08-06 8-K2026-07-22 8-K2026-06-12 8-K2026-05-14 8-K2026-05-07 10-Q2026-05-07 DEF 14A2026-04-24

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.